July 8, 2020 -- Biopharmaceutical company Xencor and biotechnology company Atreca have entered into a license agreement to research, develop, and commercialize T cell-engaging bispecific antibodies as potential cancer therapies.
Bispecific antibodies that direct T cells to tumor cells, by simultaneously binding CD3 on T cells and a target on tumor cells, have the potential to kill tumors. Xencor's engineering platform XmAb will design and manufacture CD3 bispecific antibodies and Atreca's discovery platform, including its immune repertoire capture technology, will be used to generate novel antibody-target pairs.
Their agreement calls for a three-year discovery program with each company. They will work on two programs together, and each can work on two programs separately.